Get the Stockscreener App
0.225
7.41%
-0.018
After Hours:
.23
0.005
+2.22%
Inmed Pharmaceuticals Inc stock is traded at $0.225, with a volume of 565.84K.
It is down -7.41% in the last 24 hours and up +11.28% over the past month.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
See More
Previous Close:
$0.243
Open:
$0.2347
24h Volume:
565.84K
Relative Volume:
0.09
Market Cap:
$3.17M
Revenue:
$5.49M
Net Income/Loss:
$-6.35M
P/E Ratio:
-0.0425
EPS:
-5.29
Net Cash Flow:
$-6.51M
1W Performance:
-22.41%
1M Performance:
+11.28%
6M Performance:
-7.02%
1Y Performance:
-51.19%
1-Day Range:
$0.2201
$0.2411
1-Week Range:
$0.2201
$0.2997
52-Week Range:
$0.1207
$0.7848
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Name
Inmed Pharmaceuticals Inc
Sector
Industry
Phone
(604) 669-7207
Address
1445-885 WEST GEORGIA ST., VANCOUVER
Inmed Pharmaceuticals Inc Stock (INM) Latest News
InMed Gets Nasdaq Lifeline: 20:1 Share Consolidation Plan to Avoid Delisting | INM Stock News - StockTitan
InMed files patent for Alzheimer's drug candidate INM-901 - Investing.com India
InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease - Yahoo Finance
InMed Pharmaceuticals Announces Appointment of Dr. Barry Greenberg to Scientific Advisory Board - Defense World
TSX Financials Capped Index (TTFS) QuotePress Release - The Globe and Mail
InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease - Newsfile
InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board - StockTitan
InMed Pharmaceuticals Inc (INM) Stock: A Year of Decreases and Increases - The InvestChronicle
InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying - MSN
InMed Pharmaceuticals Showcases Growth and Drug Advancements - TipRanks
InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update - StockTitan
InMed Pharmaceuticals sets date for annual shareholder meeting By Investing.com - Investing.com Australia
InMed Pharmaceuticals sets date for annual shareholder meeting - Investing.com
InMed Pharmaceuticals Announces Upcoming AGM Date - TipRanks
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
NARI’s latest rating updates from top analysts. - Knox Daily
Samlyn Capital LLC Sells 228,380 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World
Top investors say Inari Medical Inc (NARI) ticks everything they need - SETE News
A look into Indivior Plc (INDV)’s deeper side - SETE News
Does Insmed Inc (INSM) offer a good opportunity for investors? - SETE News
Stock Market Recap: Indie Semiconductor Inc (INDI) Concludes at 3.58, a -1.38 Surge/Decline - The Dwinnex
Financial Health Report: Inari Medical Inc (NARI)’s Ratios Tell a Tale - The Dwinnex
Interval Partners LP Has $2.52 Million Stock Holdings in Innoviz Technologies Ltd. (NASDAQ:INVZ) - Defense World
Seven Eight Capital LP Sells 17,969 Shares of Incyte Co. (NASDAQ:INCY) - Defense World
Shapiro Capital Management LLC Has $58.60 Million Stake in Ingredion Incorporated (NYSE:INGR) - Defense World
Ratio Analysis: Unpacking InMed Pharmaceuticals Inc (INM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Charting the Course: InMed Pharmaceuticals Inc’s INM Stock Prospects - The InvestChronicle
Inlif Ltd Files for 2M Share IPO at $4-$6/sh - Investing.com UK
Ingredion Incorporated (NYSE:INGR) Shares Acquired by Mercer Global Advisors Inc. ADV - Defense World
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Acquires 25,714 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat
Does Inspire Medical Systems Inc (INSP) offer a good opportunity for investors? - SETE News
Ratio Revelations: Inovio Pharmaceuticals Inc (INO)’s Financial Metrics in the Spotlight - The Dwinnex
Intech Investment Management LLC Acquires Shares of 17,882 Ingredion Incorporated (NYSE:INGR) - Defense World
InMode (NASDAQ:INMD) Could Be Struggling To Allocate Capital - Simply Wall St
Innoviva, Inc.'s (NASDAQ:INVA) Stock Is Going Strong: Have Financials A Role To Play? - Simply Wall St
American Century Companies Inc. Purchases 361,797 Shares of Innoviva, Inc. (NASDAQ:INVA) - MarketBeat
U.S. Dollar Index (DXY) QuotePress Release - The Globe and Mail
(INGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Infinera Corp. (INFN Stock: A Sea of Opportunity - The InvestChronicle
Insteel Industries (NASDAQ:IIIN) Sees Strong Trading Volume - MarketBeat
This trade activity should not be overlooked: InfuSystem Holdings Inc (INFU) - SETE News
Innoviz Technologies (NASDAQ:INVZ) Earns “Overweight” Rating from Cantor Fitzgerald - Defense World
Innodata Target of Unusually Large Options Trading (NASDAQ:INOD) - Defense World
Ratio Review: Analyzing Imunon Inc (IMNN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Investor’s Delight: Innodata Inc (INOD) Closes Weak at 13.95, Down -2.52 - The Dwinnex
INSP’s latest rating updates from top analysts. - Knox Daily
Innate’s Nectin-4-targeting ADC obtains IND clearance for solid tumors - BioWorld Online
Imunon Inc (IMNN) may enjoy gains as insiders got busy in the recent days - Knox Daily
Taking a Closer Look At Immersion Corp (IMMR) Following Its Recent Trade - Knox Daily
Itau Unibanco Holding S.A. Acquires New Position in Incyte Co. (NASDAQ:INCY) - Defense World
Investors Interested In Inari Medical, Inc.'s (NASDAQ:NARI) Revenues - Simply Wall St
Inmed Pharmaceuticals Inc Stock (INM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inmed Pharmaceuticals Inc Stock (INM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HULL ANDREW | Director |
Feb 21 '24 |
Buy |
0.39 |
37,500 |
14,625 |
38,258 |
| ADAMS ERIC A | President & CEO |
Feb 20 '24 |
Buy |
0.36 |
41,600 |
14,922 |
43,959 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):